#Taiwan #Taipei #AnHorn Medicines #CIPN #AH-008

AnHorn Medicines Achieves Important Regulatory Milestones for AH-008

June 22, 2026 - AnHorn Medicines has made a remarkable advancement with its lead neuroprotective candidate, AH-008, achieving dual regulatory milestones. The product gained clearance as an Investigational New Drug (IND) from the U.S. Food and Drug Administration (FDA), along with Index Case designation by the Taiwan Center for Drug Evaluation (CDE). These accomplishments signal a significant step towards introducing a first-in-class preventive treatment for chemotherapy-induced peripheral neuropathy (CIPN) into clinical trials.

Addressing a Critical Unmet Medical Need in Oncology

Chemotherapy-induced peripheral neuropathy is a prevalent and severe complication that can significantly impact a patient's quality of life. Typically associated with various cancer therapies such as taxanes, paclitaxel, and platinum-based treatments, CIPN can lead to irreversible nerve damage. This often results in pain, sensory dysfunction, and long-term impairments for cancer survivors, as well as necessitating the reduction or discontinuation of chemotherapy, thereby affecting overall treatment outcomes.

Despite its high incidence and the burden it places on patients, there are currently no therapies approved specifically for the prevention of CIPN. AnHorn Medicines aims to fill this void, showcasing the urgent need for innovative solutions in oncology supportive care.

Overview of Regulatory Milestones

The FDA’s IND clearance allows AH-008 to transition into human clinical trials, post a meticulous review of its preclinical pharmacology and toxicology data. This clearance reinforces the robustness of AH-008’s safety profile and its overall development strategy.

Simultaneously, the CDE’s Index Case designation positions AH-008 as a reference standard for new drug innovation. This recognition emphasizes the candidate’s potential to address the significant clinical gap and allows for expedited regulatory engagement.

The combination of these milestones illustrates a strong alignment from major regulatory agencies, bolstering the confidence in the AH-008 program.

Robust Preclinical Data Validation

The preclinical testing for AH-008 was crafted following the FDA’s Draft Guidance, highlighting the importance of demonstrating relevant neurotoxicity models and connections between nerve protection strategies and tangible functional outcomes. AH-008 consistently exhibited strong neuroprotective effects across diverse chemotherapy-induced neuropathy models, effectively safeguarding peripheral nerve functions while preserving the efficacy of chemotherapy treatments. These proactive studies underscore AH-008's role in halting the onset of neuropathy rather than merely addressing symptomatic relief.

This evidential build-up supports AH-008’s classification as a potential pioneer in neuroprotective therapies, paving the way for clinical evaluations under existing regulatory guidelines.

Accelerated Development Process

AnHorn Medicines has impressively pushed AH-008 from the laboratory stage to FDA IND clearance within just one year, demonstrating the company’s proficient integration of developmental science, regulatory strategy, and manufacturing processes. This swift advancement reflects AnHorn’s commitment to unifying diverse scientific efforts and supports its goal of addressing pressing unmet medical needs through innovative first-in-class therapy development.

About AH-008

AH-008 is designed as a groundbreaking neuroprotective treatment aimed at preventing CIPN by targeting the underlying mechanisms that cause chemotherapy-induced nerve injury. Unlike traditional symptomatic therapies, AH-008 works proactively throughout the treatment process to maintain nerve functionality.

About AnHorn Medicines

Founded in 2020, AnHorn Medicines is at the forefront of AI-driven biotech, focusing on creating novel drugs for oncology and supportive cancer care. The company employs its proprietary AIMCADD AI platform to enhance drug discovery through generative AI and molecular simulations, driving a new paradigm in the development of effective and safe pharmacological solutions.

For more information about AnHorn Medicines, visit www.anhornmed.com.